PE20142322A1 - Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc - Google Patents
Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gccInfo
- Publication number
- PE20142322A1 PE20142322A1 PE2014001908A PE2014001908A PE20142322A1 PE 20142322 A1 PE20142322 A1 PE 20142322A1 PE 2014001908 A PE2014001908 A PE 2014001908A PE 2014001908 A PE2014001908 A PE 2014001908A PE 20142322 A1 PE20142322 A1 PE 20142322A1
- Authority
- PE
- Peru
- Prior art keywords
- gcc
- seq
- amino acids
- antibody molecules
- targeted therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
Abstract
SE REFIERE A ANTICUERPOS Y FRAGMENTOS DE ENLACE DE ANTIGENO DE ANTICUERPOS QUE ENLAZAN GCC, EN EL QUE LOS ANTICUERPOS COMPRENDEN: A) TRES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD DE CADENA PESADA CDR1, CDR2 Y CDR3 CUYAS SECUENCIAS DE AMINOACIDOS SON LAS SEC ID N�: 21, 22 Y 23, O SEC ID N�: 33, 34 Y 35, RESPECTIVAMENTE; B) TRES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD DE CADENA LIGERA CDR1, CDR2 Y CDR3 CUYAS SECUENCIAS DE AMINOACIDOS SON LAS SEC ID N�: 27, 28 Y 29, O SEC ID N�: 39, 40 Y 41, RESPECTIVAMENTE; C) UNA REGION VARIABLE DE CADENA PESADA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID N�: 11 O 15; Y D) UNA REGION VARIABLE DE CADENA LIGERA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID N�: 13 O 17. TAMBIEN SE REFIERE A METODOS DE DIAGNOSTICO PARA IDENTIFICAR PACIENTES QUIENES DEBEN RECIBIR UNA TERAPIA DIRIGIDA A GCC UTILIZANDO LOS ANTICUERPOS ANTI-GCC PROPORCIONADOS EN LA PRESENTE INVENCION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261639376P | 2012-04-27 | 2012-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20142322A1 true PE20142322A1 (es) | 2015-01-25 |
Family
ID=49477498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001908A PE20142322A1 (es) | 2012-04-27 | 2013-04-27 | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc |
Country Status (41)
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201792376A3 (ru) | 2009-10-23 | 2018-08-31 | Милленниум Фармасьютикалз, Инк. | Молекулы анти-gcc антитела и соответствующие композиции и способы |
US20160264663A1 (en) * | 2013-10-21 | 2016-09-15 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
CA2936907C (en) | 2014-02-14 | 2022-06-07 | Arkansas Children's Hospital Research Institute, Inc. | Acetaminophen protein adducts and methods of use thereof |
AU2015358373B2 (en) | 2014-12-03 | 2021-05-27 | Arkansas Children's Research Institute | Anti-acetaminophen antibodies and acetaminophen protein adducts |
US11090383B2 (en) | 2015-10-01 | 2021-08-17 | Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
CN111448569B (zh) * | 2017-12-06 | 2023-09-26 | 文塔纳医疗系统公司 | 存储和检索数字病理学分析结果的方法 |
WO2020050722A1 (en) * | 2018-09-05 | 2020-03-12 | Universiteit Van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
CA3176119A1 (en) * | 2020-06-02 | 2021-12-09 | Teijin Pharma Limited | Anti-igf-1 receptor humanized antibody |
JP2023554467A (ja) * | 2020-12-17 | 2023-12-27 | パラソル バイオテック エルティーディー. | Gucy2c結合分子及びその使用 |
WO2024067762A1 (en) * | 2022-09-28 | 2024-04-04 | Nanjing Legend Biotech Co., Ltd. | Antibody and chimeric antigen receptors targeting gcc and methods of use thereof |
US20240165257A1 (en) | 2022-11-01 | 2024-05-23 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
ATE259648T1 (de) | 1993-10-26 | 2004-03-15 | Univ Jefferson | Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung |
US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
EP0951475B1 (en) | 1996-05-03 | 2003-07-16 | Thomas Jefferson University | Metastatic colorectal cancer vaccine |
WO1997042506A1 (en) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
AU2001249503A1 (en) | 2000-03-27 | 2001-10-08 | Thomas Jefferson University | High specificity marker detection |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
CA2434762A1 (en) | 2001-01-26 | 2002-09-19 | Joseph M. Patti | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
EP2103624B1 (en) | 2001-03-29 | 2015-03-18 | Synergy Pharmaceuticals, Inc. | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
SK288124B6 (sk) | 2001-04-13 | 2013-09-03 | Biogen Idec Ma Inc. | Anti-VLA-1 antibody, composition comprising such antibodies, isolated nucleic acids sequence, use of composition, in vitro method of determining level of VLA-1 in tissue, cell of cell line hAQC2, haAQC2, hsAQC2 or hybridoma mAQC2 and method for identifying inhibitor of I domain of integrin |
ES2289174T3 (es) | 2001-12-28 | 2008-02-01 | Amgen Fremont Inc. | Anticuerpos contra el antigeno muc-18. |
WO2004024750A2 (en) | 2002-09-13 | 2004-03-25 | Dyax Corporation | Cd44-binding ligands |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2004071436A2 (en) | 2003-02-10 | 2004-08-26 | Thomas Jefferson University | The use of gcc ligands |
AU2004239065B2 (en) | 2003-05-14 | 2008-05-15 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
US8563682B2 (en) | 2004-06-25 | 2013-10-22 | Thomas Jefferson University | Guanylylcyclase C ligands |
US7973140B2 (en) | 2004-12-21 | 2011-07-05 | Medimmune Limited | Antibodies directed to angiopoietin-2 and uses thereof |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
JP5546451B2 (ja) | 2007-06-04 | 2014-07-09 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト |
SG183701A1 (en) * | 2007-08-10 | 2012-09-27 | Centocor Ortho Biotech Inc | Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
MY153781A (en) | 2007-08-10 | 2015-03-13 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
US10031141B2 (en) * | 2007-11-30 | 2018-07-24 | Genentech, Inc. | VEGF polymorphisms and anti-angiogenesis therapy |
WO2009140436A2 (en) | 2008-05-13 | 2009-11-19 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
AU2009256156B2 (en) | 2008-06-04 | 2014-09-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010065293A1 (en) * | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
DK2881402T3 (en) * | 2009-02-12 | 2017-08-28 | Cell Signaling Technology Inc | Mutant ROS expression in human liver cancer |
AU2010217160C1 (en) | 2009-02-25 | 2015-07-02 | Diagnocure Inc. | Method for detecting metastasis of GI cancer |
JPWO2010104035A1 (ja) * | 2009-03-12 | 2012-09-13 | 学校法人近畿大学 | 非小細胞肺癌に対する化学療法の治療効果予測方法 |
WO2010147684A1 (en) | 2009-06-15 | 2010-12-23 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
US20120251509A1 (en) | 2009-10-22 | 2012-10-04 | Waldman Scott A | Cell-based anti-cancer compositions and methods of making and using the same |
EA201792376A3 (ru) * | 2009-10-23 | 2018-08-31 | Милленниум Фармасьютикалз, Инк. | Молекулы анти-gcc антитела и соответствующие композиции и способы |
EP2576622A4 (en) * | 2010-06-01 | 2013-11-27 | Univ Monash | ANTIBODIES AGAINST RECEPTOR TYROSINE KINASE C-MET |
CA2806447A1 (en) * | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Neuropilin as a biomarker for bevacizumab combination therapies |
WO2013016662A1 (en) | 2011-07-28 | 2013-01-31 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
EP2961424A4 (en) * | 2013-02-28 | 2016-10-19 | Millennium Pharm Inc | ADMINISTRATION OF AN ANTI-GCC-ANTIBODY-ACTIVE CONJUGATE AND A DNA DAMAGING ACTIVE IN THE TREATMENT OF CANCER |
-
2013
- 2013-04-27 CA CA2871614A patent/CA2871614C/en active Active
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/en active Application Filing
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en active Active
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en unknown
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko active IP Right Grant
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/en active Active
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/me unknown
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
-
2014
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-24 PH PH12014502399A patent/PH12014502399B1/en unknown
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
- 2015-09-02 HK HK15108592.8A patent/HK1208049A1/xx unknown
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja active Active
-
2019
- 2019-09-18 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20142322A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
CY1121392T1 (el) | Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης | |
CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
ES2689080T3 (es) | Anticuerpos que se unen a TL1A y sus usos | |
CY1122020T1 (el) | Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3 | |
CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
AR105724A1 (es) | Anticuerpos anti-bcma (antígeno de maduración de células b), moléculas de unión a antígenos biespecifícas que se unen a bcma y cd3 (determinante agregado 3), y usos de éstas | |
NZ773949A (en) | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof | |
ECSP17005649A (es) | Anticuerpos anti-tau humanizados | |
AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
AR109715A1 (es) | Anticuerpos anti-cd27 | |
ECSP16060104A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
PE20110797A1 (es) | Anticuerpos anti mn | |
EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы | |
NZ706377A (en) | Il-6 antagonists and uses thereof | |
PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
PE20210377A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
PE20140448A1 (es) | Moleculas de union biespecificas que se unen a vegf y ang2 | |
ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |